TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
LONDON - Fusion Antibodies plc (AIM:LON:FAB) has received a patent issue notification from the United States Patent and Trademark Office regarding its application for an "Antibody Library and Method" patent, the company announced Thursday.
The notification indicates that the patent will be granted on August 5, 2025. The patent covers the library of antibodies currently screened within Fusion’s OptiMAL platform and the method for designing additional libraries.
According to the company, this technology is central to Fusion’s offering of "Opti" designed libraries for applications including antibody discovery, affinity maturation, and sequence optimization.
Fusion Antibodies, which specializes in pre-clinical antibody discovery, engineering and supply for therapeutic drug and diagnostic applications, is also pursuing patent applications for this technology in other territories including Europe, China and Japan.
"This news takes us another step forward in gaining patent protection for our Opti discovery platforms including OptiMAL," said Adrian Kinkaid, CEO of Fusion Antibodies, in the press release statement. "We believe [it] would represent significant value creation for the business."
The patent issue notification is a document informing an applicant that their patent application has been approved and scheduled for granting, though the patent itself has not yet been formally issued.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.